A Prospective, Open-Label, Umbrella, Phase II Study of Lucamtasutab for Injection Combined with Targeted Therapy as Neoadjuvant Treatment for Non-Small Cell Lung Cancer Harboring Rare Mutations (ChiCTR) - Oct 16, 2026 - P2 | N=84 | Not yet recruiting | Sponsor: Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
New P2 trial • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • KRAS • MET • RET • ROS1
|